Loading...
21 casirivimab/imdevimab COVID-19 controlled studies, 9 RCTs
https://c19regn.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Regeneron (RCT) 38%
0.62 [0.29-1.33]
recov. time
92 (n)
91 (n)
Improvement, RR [CI] Treatment Control Regeneron (RCT) 54%
0.46 [0.19-1.13]
recov. time
92 (n)
91 (n)
Regeneron (RCT) 71%
0.29 [0.17-0.48]
death/hosp.
18/1,355
62/1,341
Regeneron (RCT) 70%
0.30 [0.13-0.68]
death/hosp.
7/736
24/748
Regeneron (RCT) 29%
0.71 [0.60-0.85]
recov. time
1,355 (n)
1,341 (n)
Regeneron (RCT) 29%
0.71 [0.60-0.85]
recov. time
736 (n)
748 (n)
Weinreich (RCT) 50%
0.50 [0.09-2.72]
death
2/2,091
4/2,089
Weinreich (RCT) 67%
0.33 [0.03-3.17]
death
1/1,355
3/1,341
Weinreich (RCT) -2%
1.02 [0.06-16.2]
death
1/736
1/748
Weinreich (RCT) 71%
0.29 [0.17-0.48]
death/hosp.
18/1,355
62/1,341
Weinreich (RCT) 70%
0.30 [0.13-0.68]
death/hosp.
7/736
24/748
Weinreich (RCT) 29%
0.71 [0.58-0.87]
recov. time
1,355 (n)
1,341 (n)
Weinreich (RCT) 29%
0.71 [0.58-0.87]
recov. time
736 (n)
748 (n)
Webb 98%
0.02 [0.00-0.27]
death
0/115
57/5,536
Webb 91%
0.09 [0.01-0.63]
hosp.
1/115
538/5,536
Cooper 77%
0.23 [0.03-1.65]
death
1/1,148
33/8,534
Cooper 48%
0.52 [0.23-1.20]
ICU
6/1,148
85/8,534
Cooper 52%
0.48 [0.35-0.64]
hosp.
45/1,148
703/8,534
Kakinoki 58%
0.42 [0.17-0.92]
progression
13/55
22/53
Komagamine 77%
0.23 [0.01-4.63]
ventilation
0/53
2/75
Komagamine 92%
0.08 [0.00-1.32]
ICU
0/53
7/75
Komagamine 68%
0.32 [0.13-0.68]
progression
8/53
33/75
Komagamine 29%
0.71 [0.58-0.87]
hosp. time
53 (n)
75 (n)
Suzuki (PSM) -200%
3.00 [0.12-73.3]
death
1/222
0/222
Suzuki 60%
0.40 [0.05-3.45]
death
1/314
5/635
Suzuki (PSM) 45%
0.55 [0.31-0.96]
progression
17/222
31/222
Suzuki 50%
0.50 [0.31-0.80]
progression
34/314
70/365
O'Brien (DB RCT) 85%
0.15 [0.01-2.78]
hosp.
0/100
3/104
O'Brien (DB RCT) 92%
0.08 [0.00-1.37]
hosp./ER
0/100
6/104
O'Brien (DB RCT) 33%
0.67 [0.43-0.98]
symp. case
29/100
44/104
O'Brien (DB RCT) 40%
0.60 [0.45-0.81]
viral load
100 (n)
104 (n)
Shopen -46%
1.46 [0.73-2.67]
severe case
24/116
26/243
Osugi 24%
0.76 [0.23-2.49]
hosp.
4/30
15/74
Wei 61%
0.39 [0.26-0.60]
death/hosp.
23/1,116
27/5,291
Wei 61%
0.39 [0.30-0.51]
hosp.
59/3,280
75/16,284
Wilden 82%
0.18 [0.05-0.50]
hosp.
n/a
n/a
Faraone 92%
0.08 [0.00-1.24]
death
0/11
8/23
Faraone 94%
0.06 [0.00-0.76]
oxygen
0/11
15/23
Miyashita 33%
0.67 [0.11-3.97]
ventilation
2/461
3/461
Miyashita 46%
0.54 [0.35-0.82]
oxygen
30/461
56/461
Horby (RCT) 6%
0.94 [0.86-1.02]
death
943/4,839
1,029/4,946
Horby (RCT) -1%
1.01 [0.90-1.14]
ventilation
484/4,556
488/4,642
Horby (RCT) 21%
0.79 [0.69-0.91]
death
396/1,633
452/1,520
Horby (RCT) 13%
0.87 [0.73-1.05]
ventilation
190/1,599
202/1,484
Somersa.. (DB RCT) 36%
0.64 [0.44-0.93]
death
59/804
45/393
Somersa.. (DB RCT) 56%
0.44 [0.26-0.76]
death
24/360
24/160
Somersa.. (DB RCT) 21%
0.79 [0.44-1.40]
death
26/369
18/201
Somersa.. (DB RCT) 31%
0.69 [0.50-0.95]
death/int.
82/804
58/393
Somersa.. (DB RCT) 29%
0.71 [0.53-0.96]
no disch.
92/804
63/393
McCreary (PSM) 93%
0.07 [0.01-0.51]
death
1/652
29/1,304
McCreary (PSM) 56%
0.44 [0.28-0.68]
death/hosp.
22/652
101/1,304
McCreary (PSM) 48%
0.52 [0.33-0.82]
hosp.
22/652
85/1,304
McCreary (PSM) 40%
0.60 [0.43-0.85]
hosp./ER
40/652
133/1,304
Regeneron (RCT) 94%
0.06 [0.00-1.10]
symp. case
0/186
8/223
Regeneron (RCT) 48%
0.52 [0.25-1.07]
cases
10/186
23/223
Regeneron (DB RCT) 92%
0.08 [0.00-1.36]
hosp.
0/841
6/842
Regeneron (DB RCT) 81%
0.19 [0.12-0.30]
cases
20/841
108/842
Regeneron (DB RCT) 82%
0.18 [0.08-0.41]
cases
7/841
38/842
Regeneron (DB RCT) 89%
0.11 [0.01-2.06]
hosp./ER
0/753
4/752
Regeneron (DB RCT) 81%
0.19 [0.10-0.35]
symp. case
11/753
59/752
Regeneron (DB RCT) 62%
0.38 [0.23-0.61]
recov. time
753 (n)
752 (n)
Regeneron (DB RCT) 69%
0.31 [0.17-0.55]
viral time
753 (n)
752 (n)
Isa (DB RCT) 93%
0.07 [0.01-0.28]
symp. case
3/729
13/240
Isa (DB RCT) 93%
0.07 [0.01-0.28]
cases
0/729
10/240
casirivimab/imdevimab COVID-19 outcomes c19regn.com Jun 2022
Favors casirivimab/im..
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit
